Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sorrento Therapeutics, Inc. - Common Stock (NQ:SRNE)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sorrento Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Market Briefing For Monday, Aug. 2
We're 'not' in a global financial crisis; but we are failing the 'synchronized global recovery', due to the worldwide pandemic. 
Via Talk Markets
Market Briefing For Thursday, July 29
Disarming SARS-CoV-2 with pharmaceutical drugs is the 'holy grail' to end the COVID-19 panic, and generally eliminate the panic pressures for vaccines. 
Via Talk Markets
Exposures COVID-19
Market Briefing For Wednesday, July 28
Tolls being taken out of the market for those overstaying not just Chinese stocks, but the S&P and NDX behemoths as well. Solid earnings are 'in the mix' (discounted) of course, and it's the guidance... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Market Briefing For Thursday, July 22
The post-COVID era has not arrived yet, and that cuts to the chase of what's bothering markets and prospects for the economy. The optimistic hope is to keep everything open on a presumed basis, because... 
Via Talk Markets
Topics Economy
Exposures Economy
Unusual Options Activity Insight: Sorrento Therapeutics
Shares of Sorrento Therapeutics (NASDAQ:SRNE) saw some unusual options activity on Wednesday. Following the unusual option alert, the stock price moved up to $9.16. Sentiment:... 
Via Benzinga
Why Sorrento Therapeutics' Stock Is Trading Higher Today
Sorrento Therapeutics (NASDAQ:SRNE) shares are trading hig... 
Via Benzinga
Market Briefing For Wednesday, July 21
Via Talk Markets
Delta Variant Infections of COVID Rising Quickly & Now Responsible for 83% of All U.S. Cases
Via FinancialNewsMedia
Exposures COVID-19
Sorrento Starts Patient Dosing In Mid-Stage COVID-19 Trial With Nasal Neutralizing Antibody
Sorrento Therapeutics Inc (NASDAQ: SRNE) has started dosing COVID-19 patients in its Phase 2 efficacy trial. This study uses a decentralized design where... 
Via Benzinga
Exposures COVID-19
Market Briefing For Wednesday, July 14
Negative divergences increasingly creeping into the NY market are reflected a good bit by the S&P shuffles, and overall big-board technicals. Though, yields were up with a mediocre Treasury Auction,... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Unusual Options Activity Insight: Sorrento Therapeutics
On Monday, shares of Sorrento Therapeutics (NASDAQ:SRNE) saw unusual options activity. After the option alert, the stock price moved down to $8.31. Sentiment: BULLISH Option... 
Via Benzinga
Why Sorrento Therapeutics Is Down 9% This Week
Investors apparently weren't impressed by good news about the company's promising RTX. 
Via The Motley Fool
Why Sorrento Therapeutics Stock Gained 29% Last Month
The rally has more to do with the stock's pre-June circumstances than recent news. 
Via The Motley Fool
Exposures COVID-19
Market Briefing For Thursday, July 8
Economic instability was a concern of the FOMC Minutes, with debates as to whether or not the country is recovering faster than they expected. 
Via Talk Markets
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Opiant Pharmaceuticals (NASDAQ:OPNT 
Via Benzinga
Sorrento To Start Testing Non-Opioid Candidate In Osteoarthritis-Related Knee Pain
The FDA has signed off Sorrento Therapeutics Inc's (NASDAQ: SRNE) Phase 2 study of Resiniferatoxin (RTX) for moderate-to-severe osteoarthritis of the knee pain... 
Via Benzinga
Exposures Product Safety
Why Sorrento Therapeutics Is Climbing Today
Rising numbers of new COVID-19 cases might have investors anticipating strong demand for the company's 15-minute test. 
Via The Motley Fool
Exposures COVID-19
Cramer Gives His Opinion On Virgin Galactic, Zynex And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said Virgin Galactic Holdings Inc (NYSE: SPCE) is a very expensive stock. It had a nice run, but he would look for... 
Via Benzinga
Market Briefing For Thursday, July 1
The second quarter of 2021 concluded on a high note, a new record S&P high, which was a part of Wednesday's rotational action focused primarily on big cap stocks influential enough to contribute to the... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Sorrento Therapeutics Forms Bullish Pattern, Options Traders Place Bets
Sorrento Therapeutics, Inc (NASDAQ:SRNE) shot up over 10% ... 
Via Benzinga
20 Stocks Moving in Friday's Pre-Market Session
Gainers Fuwei Films (Holdings) Co., Ltd. (NASDAQ: FFHL) rose 83.4% to $16.34 in pre-market trading after the company reported a sharp rise in Q1 earnings and sales. Grove, Inc. (... 
Via Benzinga
Why Sorrento Therapeutics Stock Jumped 10.6% Today
The company is setting up a subsidiary to launch its COVID-19 test in Mexico. 
Via The Motley Fool
Exposures COVID-19
The News That Has Sorrento Therapeutics Trading Higher Today
Sorrento Therapeutics Inc (NASDAQ: SRNE) is trading higher Thursday after the company received EUA approval and a product import license from COFEPRIS for its rapid COVID-19 test... 
Via Benzinga
Exposures COVID-19
Market Briefing For Thursday, Jun. 24
Around record S&P levels, discussions drone-on about crypto or the Fed, and inflation, along with vague discussions about returning risk from COVID. 
Via Talk Markets
Topics Economy Stocks
Exposures Interest Rates US Equities
Market Briefing For Wednesday, Jun. 23
The attractiveness of stocks and sectors vary so widely now, that most bull / bear debates are somewhat academic, even though logic for a correction is there. 
Via Talk Markets
Sorrento Therapeutics Is Forming Pennant Pattern: Technical Levels To Watch
Sorrento Therapeutics Inc. (NASDAQ: SRNE) shares moved higher Tuesday after the company announced Phase 2 Abivertinib clinical studies have completed patient enrollment in the U.S... 
Via Benzinga
Sorrento Therapeutics Concludes Enrollment In Abivertinib Mid-Stage COVID-19 Trials In US, Brazil
Sorrento Therapeutics Inc (NASDAQ: SRNE) has completed enrollment for its Phase 2 trial of Abivertinib in hospitalized COVID-19 patients in Brazil. This... 
Via Benzinga
Exposures COVID-19
Market Briefing For Thursday, Jun. 17
Vulnerability is bifurcated, just like sector rotation indicated all year thus far. It is typical to see risk increased amidst superficial optimism at high S&P levels, but that's not really what moved... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Market Briefing For Tuesday, Jun. 15
Conclusions can't be drawn about the upcoming FOMC meetings by analysts, who mostly continue to debate the issues we know: hot inflation numbers that skewed the CPI, whether that's transitory or not,... 
Via Talk Markets
Why Sorrento Therapeutics Stock Flew Nearly 7% Higher on Monday
The company got the green light to launch phase 2 testing in the U.K. for its experimental COVID-19 treatment. 
Via The Motley Fool
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.